Mergers & Acquisitions ·
Eton pays $10M upfront for exclusive U.S. rights to LIBERVANT buccal film from Aquestive
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals entered into an exclusive license and supply agreement with Aquestive Therapeutics to commercialize LIBERVANT (diazepam) buccal film in the United States. Eton paid a $10 million upfront fee and faces potential regulatory and commercial milestone payments totaling up to $47.5 million, plus mid-teens percentage royalties on net sales. The product has received tentative FDA approval for patients aged 2-5 and 12+, with full approval expected after January 10, 2027, and a PDUFA date of March 29, 2027, for ages 6-11. Eton anticipates a commercial launch in April 2027. The company operates as an innovative pharmaceutical firm focused on developing and commercializing treatments for rare diseases.